Searchable abstracts of presentations at key conferences in endocrinology

ea0073s10.2 | Symposium 10: New approaches in pituitary pathologies from a multidisciplinary team | ECE2021

Tumor or not tumor and what’s new in pituitary pathology

Trouillas Jacqueline

Pituitary adenohypophyseal tumors are considered benign and termed “adenomas” but can also be invasive, “aggressive” and malignant with metastases (carcinoma). Taking into account this variability in behavior and the oncological definition, pathologists have proposed changing the term adenoma to tumor. Indeed, “tumor designates a neoplasm which is benign or malignant”. The invasion of the surrounding tissues is a criterion of malignancy. For this ...

ea0099oc9.1 | Oral Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

Differential gene expression in dopamine agonist sensitive and resistant human prolactinomas

Delgrange Etienne , Trouillas Jacqueline , Wierinckx Anne

Dopamine agonists (DAs) are usually used as first line treatment in prolactinomas. Some tumors do not normalize prolactin levels under treatment and demonstrate a more aggressive course. The mechanisms underlying this chemoresistance are poorly understood. Previous gene expression studies have focused on candidate genes such as the DA receptor 2 (DRD2) or the nerve growth factor (NGF), but transcriptome analyses comparing tumors resistant and responsive to DA are still lacking...

ea0014p648 | (1) | ECE2007

Ovarian hyperstimulation syndrome during IVF induction revealing a gonadotroph adenoma

Lecomte Pierre , Chabrolle Christine , Pierre Peggy , Jan Michel , Trouillas Jacqueline

Gonadotroph adenomas are usually detected by their local mass effects. Spontaneous ovarian hyperstimulation syndrome (OHS) has rarely been described as the main manifestation of gonadotroph adenomas in young women. We present a case with a prolonged OHS occurring during IVF ovarian induction leading to the discovery of a FSH pituitary tumour.Case report: A 36 year-old, normal weight woman with 2 years primary infertility linked to oligomenorrhea and anov...

ea0067o36 | Oral Presentations | EYES2019

Unusual cause of gigantism – Growth hormone releasing hormone (GHRH)-secreting pancreatic neuroendocrine tumour in a patient with multiple endocrine neoplasia type 1 (MEN1)

Nadhamuni Vinaya Srirangam , Iacovazzo Donato , Evanson Jane , Trouillas Jacqueline , Kurzawinski Tom , Bhattacharya Satya , Korbonits Marta

Background: Gigantism is a rare condition with accelerated growth in childhood when the epiphyseal plates are not fused. Most cases are due to growth hormone (GH) secretion from a pituitary adenoma. Rarer causes of GH-related gigantism include somatotroph hyperplasia as part of McCune-Albright syndrome, Carney complex, X-linked acrogigantism or ectopic GHRH production.Case presentation: An 18-year-old male with c.249_252delGTCT;p.I85Sfs MEN1 mut...

ea0049oc12.2 | Pituitary Clinical | ECE2017

Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: Results from a European Society of Endocrinology (ESE) survey

McCormack Ann , Dekkers Olaf M , Petersenn Stephan , Popovic Vera , Trouillas Jacqueline , Raverot Gerald , Burman Pia

Objective: To collect clinical and treatment outcome data in a large patient cohort, and specifically to report experience with temozolomide (TMZ).Design: Cohort study based on an electronic survey open for participation to ESE members Dec 2015-Nov 2016.Results: Reports on 167 patients, 40 pituitary carcinomas, and 127 aggressive pituitary tumours were obtained. Median age at diagnosis was 43 (range 4–79) years. 59% of tumours...

ea0049gp194 | Pituitary & endocrine Tumours | ECE2017

Serotonin, ATRX and DAXX as differential diagnostic markers of neuroendocrine tumours (NETs) in the sellar region. An immunohistochemical study in a large series of pituitary adenomas and in a non-pituitary NET

Casar-Borota Olivera , Botling Johan , Granberg Dan , Wikstrom Johan , Ponten Fredrik , Trouillas Jacqueline

We present a case of a patient with a locally invasive, serotonin- and ACTH-reactive tumour in the sellar region, filling the sphenoid sinus and expanding into the epipharynx. Clinical examination completed by 68-Gallium-DOTA-TOC PET revealed tracer uptake in the sellar tumour as well as in a 7 mm lesion in the pancreatic tail. A differential diagnosis between silent corticotroph adenoma and another primary or secondary neuroendocrine tumour (NET) with ACTH-expression was diff...

ea0041ep862 | Pituitary - Basic | ECE2016

The silent somatotroph tumours

Chinezu Laura , Vasiljevic Alexandre , Lapoirie Marion , Trouillas Jacqueline , Jouanneau Emmanuel , Raverot Gerald

Introduction: Silent somatotroph tumours are GH immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. In our series, they represent 16% of all the somatotroph pituitary tumours. The aim of our study was to compare the somatotroph tumours with and without acromegaly to a better characterization of these silent tumours.Materials and methods: Fifty-nine tumours with acromegaly and 21 silent somatotroph tumours were studi...

ea0041ep880 | Pituitary - Clinical | ECE2016

Predictive factors of surgical outcomes in acromegaly: what’s new in 2016?

Lapoirie Marion , Vasiljevic Alexandre , Rabilloud Muriel , Lapras Veronique , Chinezu Laura , Trouillas Jacqueline , Jouanneau Emmanuel , Raverot Gerald

Introduction: In the era of personalized patient management in acromegaly, transsphenoidal surgery remains a treatment of choice in cases where surgical cure can be expected. In order to better target these patients and to assess the risk of persistence/progression disease, we evaluated clinical, hormonal, radiological and pathological predictors of surgical outcome in acromegaly.Methods: A single-institution retrospective study from 2009 to 2015 was per...

ea0032oc1.4 | Pituitary & Molecular Endocrinology | ECE2013

BKM120, a pure PI3K inhibitor: a promising treatment for aggressive pituitary tumors or pituitary carcinomas

Auger Carole , Rachwan Alexa , Chanal Marie , Raverot Veronique , Chevallier Pascale , Trouillas Jacqueline , Raverot Gerald

Introduction: 15% of pituitary tumors are considered as aggressive based on resistance to conventional treatment. Less than 40% of these cases respond to temozolomide treatment underlining the need for new therapeutic options. The PI3K/Akt/mTOR pathway, upregulated in different pituitary tumors subtypes, can be targeted by different drugs in particular BKM 120, a pure PI3K inhibitor, and BEZ235, a dual PI3K/mTOR inhibitor.Objective: To study the anti-tum...